Stock Analysis
Peijia Medical (HKG:9996) Full Year 2023 Results
Key Financial Results
- Revenue: CN¥441.1m (up 76% from FY 2022).
- Net loss: CN¥392.5m (loss narrowed by 3.7% from FY 2022).
- CN¥0.58 loss per share (improved from CN¥0.61 loss in FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Peijia Medical Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 5.0%. Earnings per share (EPS) also missed analyst estimates by 12%.
The primary driver behind last 12 months revenue was the Neurointerventional Business segment contributing a total revenue of CN¥255.6m (58% of total revenue). The largest operating expense was Sales & Marketing costs, amounting to CN¥325.0m (45% of total expenses). Explore how 9996's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Medical Equipment industry in Hong Kong.
Performance of the Hong Kong Medical Equipment industry.
The company's shares are down 32% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Peijia Medical has 3 warning signs (and 2 which are a bit unpleasant) we think you should know about.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About SEHK:9996
Peijia Medical
Engages in the research and development of transcatheter valve therapeutic and neuro interventional procedural medical devices.
Excellent balance sheet and good value.
